Email updates

Keep up to date with the latest news and content from Journal of Hematology & Oncology and BioMed Central.

Open Access Review

Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology

Katerina Pilatova16, Kristina Greplova1, Regina Demlova256, Beatrix Bencsikova3, Giannoula Lakka Klement46 and Lenka Zdrazilova-Dubska156*

Author Affiliations

1 Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic

2 Department of Clinical Evaluation, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic

3 Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic

4 Center of Cancer Systems Biology, Steward St. Elizabeth’s Medical Center Pediatric Hematology Oncology, Tufts University School of Medicine, Boston, MA, USA

5 Department of Pharmacology, Medical Faculty, Masaryk University, Kamenice 5, Brno 625 00, Czech Republic

6 Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic

For all author emails, please log on.

Journal of Hematology & Oncology 2013, 6:42  doi:10.1186/1756-8722-6-42

Published: 24 June 2013

Abstract

With the recent addition of anti-angiogenic agents to cancer treatment, the angiogenesis regulators in platelets are gaining importance. Platelet factor 4 (PF-4/CXCL4) and Connective tissue activating peptide III (CTAP-III) are two platelet-associated chemokines that modulate tumor angiogenesis, inflammation within the tumor microenvironment, and in turn tumor growth. Here, we review the role of PF-4 and CTAP-III in the regulation of tumor angiogenesis; the results of clinical trial using recombinant PF-4 (rPF-4); and the use of PF-4 and CTAP-III as cancer biomarkers.

Keywords:
Platelet; PF-4; CTAP-III; Cancer; Angiogenesis; IL-8; Inflammation